164 related articles for article (PubMed ID: 29119292)
1. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
2. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
Woodcock HV; Molyneaux PL; Maher TM
Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
[TBL] [Abstract][Full Text] [Related]
3. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.
Valenzuela C; Torrisi SE; Kahn N; Quaresma M; Stowasser S; Kreuter M
Respir Res; 2020 Jan; 21(1):7. PubMed ID: 31906942
[TBL] [Abstract][Full Text] [Related]
4. Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.
Liu F; Bayliss G; Zhuang S
Clin Sci (Lond); 2019 Jun; 133(12):1309-1320. PubMed ID: 31217321
[TBL] [Abstract][Full Text] [Related]
5. Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients.
Nili M; Epstein AJ; Nunag D; Olson A; Borah BJ
BMC Pulm Med; 2024 Mar; 24(1):141. PubMed ID: 38504247
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib-A case of treating concurrent idiopathic pulmonary fibrosis and non-small cell lung cancer.
Dabholkar S; Gao B; Chuong B
Respirol Case Rep; 2022 Feb; 10(2):e0902. PubMed ID: 35059200
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors.
Savelieva M; Woo MM; Schran H; Mu S; Nedelman J; Capdeville R
Eur J Clin Pharmacol; 2015 Jun; 71(6):663-672. PubMed ID: 25939707
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib as the First Treatment for Group of Progressive Interstitial Lung Diseases: A Review of Patent Literature.
Trivedi MD; Dubal G; Vora PA
Recent Adv Inflamm Allergy Drug Discov; 2023; 17(2):96-109. PubMed ID: 37710999
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib-associated enterocolitis with intractable diarrhea: a case report.
Miyaguchi K; Tsuzuki Y; Uemuara H; Ishizawa K; Shinomiya S; Matsumoto H; Shiomi R; Ohgo H; Nagata M; Nakamoto H; Imaeda H
Clin J Gastroenterol; 2024 Apr; 17(2):271-275. PubMed ID: 38042763
[TBL] [Abstract][Full Text] [Related]
10. Resolving the scar of pulmonary fibrosis.
Downey GP
N Engl J Med; 2011 Sep; 365(12):1140-1. PubMed ID: 21992127
[No Abstract] [Full Text] [Related]
11. Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro.
Zeinali S; Bichsel CA; Hobi N; Funke M; Marti TM; Schmid RA; Guenat OT; Geiser T
Angiogenesis; 2018 Nov; 21(4):861-871. PubMed ID: 29967964
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis.
Podolanczuk AJ; Aronson KI
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38302183
[No Abstract] [Full Text] [Related]
13. Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease.
Lo A; Borin MT; Bourdet DL
Clin Pharmacokinet; 2021 Mar; 60(3):391-401. PubMed ID: 33124005
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of crenolanib in children and young adults with brain tumors.
Bisbee C; Campagne O; Gajjar A; Tinkle CL; Stewart CF
Cancer Chemother Pharmacol; 2022 Apr; 89(4):459-468. PubMed ID: 35212779
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib-induced osteomyelitis of the jaw against the background of COVID-19 infection.
Kudva A; Saha M; G S; S A; Sharma S
J Stomatol Oral Maxillofac Surg; 2024 Apr; 125(2):101651. PubMed ID: 37778458
[TBL] [Abstract][Full Text] [Related]
16. Safety of nintedanib before lung transplant: an Italian case series.
Balestro E; Solidoro P; Parigi P; Boffini M; Lucianetti A; Rea F
Respirol Case Rep; 2018 May; 6(4):e00312. PubMed ID: 29564136
[TBL] [Abstract][Full Text] [Related]
17. Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib.
Imai R; Tomishima Y
Respirol Case Rep; 2020 Mar; 8(2):e00533. PubMed ID: 32082576
[TBL] [Abstract][Full Text] [Related]
18. Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non-small cell lung cancer based on bintrafusp alfa trials.
Milenković-Grišić AM; Terranova N; Mould DR; Vugmeyster Y; Mrowiec T; Machl A; Girard P; Venkatakrishnan K; Khandelwal A
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):143-153. PubMed ID: 38087967
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future.
Nathan SD
Am J Respir Crit Care Med; 2019 Dec; 200(12):1459-1461. PubMed ID: 31425662
[No Abstract] [Full Text] [Related]
20. Successful nintedanib desensitization: Due to two cases.
Tepetam FM; Özden Ş; Duman D
Tuberk Toraks; 2023 Mar; 71(1):105-106. PubMed ID: 36912414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
